StockData
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc. (MRVI) company profile

MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)

Close on Nov 17, 2026Market cap $1.89BP/E –Yield –

About Maravai LifeSciences

Pharmaceutical Preparations, SIC 2834

Maravai LifeSciences Holdings provides products and services that support the development of drug therapies, vaccines, and diagnostics, as well as human disease research. The business operates through two primary segments: TriLink and Cygnus. The TriLink segment supplies modified nucleic acids and associated technologies, including messenger RNA, CleanCap capping reagents, ModTail modifications, oligonucleotides, nucleoside triphosphates, specialty enzymes, and contract synthesis services. The Cygnus segment focuses on biologics safety testing solutions, offering host cell protein detection kits, viral clearance prediction assays, auxiliary reagents, and custom analytical testing. Its client base spans biopharmaceutical corporations, emerging biotechnology enterprises, academic and life science research institutions, and diagnostic organizations.

As of late 2025, the enterprise employs 435 full-time personnel globally. It serves clients across roughly 60 nations outside the United States using direct sales teams and distributor partners. Operational sites supporting manufacturing, analysis, and distribution are situated in San Diego, California; Leland, North Carolina; Sterling, Virginia; and Jupiter, Florida. The provided text does not state a corporate headquarters.

Summary of the business section of Maravai LifeSciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Maravai LifeSciences Holdings, Inc.
Headquarters
San Diego, CA
Address
10770 Wateridge Circle Suite 200 92121
Phone
(858) 546-0004
Employees
435, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
MRVI
Exchange
Nasdaq
IPO date
Nov 23, 2020
Shares outstanding
260M, Jul 31, 2026
Public float
$300.00M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1823239
CUSIP
56600D107
ISIN
US56600D1072
FIGI
BBG00Y1DFV91
Share class FIGI
BBG00Y1DFW44
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Bernd BrustChief Executive Officer, Director1,969,520
Rajesh AsarpotaChief Financial Officer412,555
Kurt OreshackGeneral Counsel335,767
Christine DolanSee Remarks425,318
Peter Michael LeddySee Remarks727,177
Kevin HerdeChief Financial Officer674,636
William E. Martin IiiChief Executive Officer1,814,643
Rebecca BuzzeoSee Remarks310,933
Andrew BurchSee Remarks369,183
Gregory T. LucierDirector311,200
Sean Laurence CunninghamDirector184,348
R. Andrew EckertDirector412,183
Luke Joseph MarkerDirector184,348
Susannah GrayDirector216,200
Constantine S. MihasDirector184,348
John A. DeFordDirector205,478
Murali PrahaladDirector154,607
Jessica HopfieldDirector199,907
Benjamin James DavermanDirector138,055

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mr.Burst
$10.13M$14.01M$2.00M$11$131
FY2025
Mr.Martin
$3.85M-$1.97M$2.00M$11$131
FY2024$6.38M$5.83M$2.43M$18$99
FY2023
Mr.Hull
$5.22M$1.64M$2.72M$22$100
FY2023
Mr.Martin
$2.30M-$3.81M$2.72M$22$100
FY2022$5.48M$3.04M$2.21M$48$97

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Bernd Brust
Chief Executive Officer
$388.86K–$7.66M$1.46M$425.34K$195.50K$10.13M–
William E. Martin III
Former Chief Executive Officer
$345.00K–$2.60M––$896.71K$3.85M-40%
Raj Asarpota
Chief Financial Officer
$253.37K$200.00K$2.17M$483.33K$195.14K$202.46K$3.51M–
Kevin Herde
Former Chief Financial Officer
$247.77K–$1.04M––$441.55K$1.73M-26%
Kurt Oreshack
Secretary and General Counsel
$455.44K–$781.07K–$225.32K$9.15K$1.47M–
Christine Dolan
Executive Vice President and General Manager, Cygnus
$450.97K–$650.89K–$343.19K$9.15K$1.45M–
Peter Leddy
Chief Administrative Officer
$372.20K–$1.04M–$115.84K$320.35K$1.85M-22%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 23, 2020
Offer price
$27.00
Securities offered
60,000,000
Gross proceeds
$1.62B
Exchange
Nasdaq
First trading day
Nov 20, 2020
First-day close
$29.85+10.6%
Lock-up ends (est.)
May 19, 2021

“See “Management—Corporate Governance—Controlled Company Status.” PRICE $27.00 A SHARE Per share Total Initial public offering price $ 27.0000 $ 1,620,000,000 Underwriting discounts and commissions (1) $ 1.4850 $ 89,100,000 Proceeds, before expenses, to Maravai LifeSciences Holdings, Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 435 full-time employees globally.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?